Search Results - "Mamo, Mulugeta"

Yield stability and adaptability of lowland sorghum (Sorghum bicolor (L.) Moench) in moisture-deficit areas of Northeast Ethiopia by Worede, Fisseha, Mamo, Mulugeta, Assefa, Solomon, Gebremariam, Tsegaye, Beze, Yemata

“…Genotype-environment interaction (GxE) is a common phenomenon in sorghum. The effect of GxE can be reduced by identifying stable genotypes across environments…”
Get full text

Assessment of type II diabetes mellitus drug therapy in diabetes clinic of a tertiary care teaching hospital in Addis Ababa by Hawaze, Segewkal, Anshabo, AbelTesfaye, Asfaw, AlemsegedAyele, Mamo, NahomMulugeta

“…Prevalence of type II diabetes mellitus(T2DM) is substantially increasing in Ethiopia but there are no studies on its drug therapy. To assess drug therapy for…”
Get full text

Facilitating unambiguous NMR assignments and enabling higher probe density through selective labeling of all methyl containing amino acids by Proudfoot, Andrew, Frank, Andreas O., Ruggiu, Fiorella, Mamo, Mulugeta, Lingel, Andreas

“…The deuteration of proteins and selective labeling of side chain methyl groups has greatly enhanced the molecular weight range of proteins and protein…”
Get full text

Design and Discovery of N‑(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic by Ramurthy, Savithri, Taft, Benjamin R, Aversa, Robert J, Barsanti, Paul A, Burger, Matthew T, Lou, Yan, Nishiguchi, Gisele A, Rico, Alice, Setti, Lina, Smith, Aaron, Subramanian, Sharadha, Tamez, Victoriano, Tanner, Huw, Wan, Lifeng, Hu, Cheng, Appleton, Brent A, Mamo, Mulugeta, Tandeske, Laura, Tellew, John E, Huang, Shenlin, Yue, Qin, Chaudhary, Apurva, Tian, Hung, Iyer, Raman, Hassan, A. Quamrul, Mathews Griner, Lesley A, La Bonte, Laura R, Cooke, Vesselina G, Van Abbema, Anne, Merritt, Hanne, Gampa, Kalyani, Feng, Fei, Yuan, Jing, Mishina, Yuji, Wang, Yingyun, Haling, Jacob R, Vaziri, Sepideh, Hekmat-Nejad, Mohammad, Polyakov, Valery, Zang, Richard, Sethuraman, Vijay, Amiri, Payman, Singh, Mallika, Sellers, William R, Lees, Emma, Shao, Wenlin, Dillon, Michael P, Stuart, Darrin D

“…Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling,…”
Get full text

Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors by Lu, Yipin, Knapp, Mark, Crawford, Kenneth, Warne, Robert, Elling, Robert, Yan, Kelly, Doyle, Michael, Pardee, Gwynn, Zhang, Li, Ma, Sylvia, Mamo, Mulugeta, Ornelas, Elizabeth, Pan, Yue, Bussiere, Dirksen, Jansen, Johanna, Zaror, Isabel, Lai, Albert, Barsanti, Paul, Sim, Janet

“…ATR, a protein kinase in the PIKK family, plays a critical role in the cell DNA-damage response and is an attractive anticancer drug target. Several potent and…”
Get full text

Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design by Hobson, Adrian D, Judge, Russell A, Aguirre, Ana L, Brown, Brian S, Cui, Yifang, Ding, Ping, Dominguez, Eric, DiGiammarino, Enrico, Egan, David A, Freiberg, Gail M, Gopalakrishnan, Sujatha M, Harris, Christopher M, Honore, Marie P, Kage, Karen L, Kapecki, Nicolas J, Ling, Christopher, Ma, Junli, Mack, Helmut, Mamo, Mulugeta, Maurus, Stefan, McRae, Bradford, Moore, Nigel S, Mueller, Bernhard K, Mueller, Reinhold, Namovic, Marian T, Patel, Kaushal, Pratt, Steve D, Putman, C. Brent, Queeney, Kara L, Sarris, Kathy K, Schaffter, Lisa M, Stoll, Vincent, Vasudevan, Anil, Wang, Lei, Wang, Lu, Wirthl, William, Yach, Kimberly

“…A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor…”
Get full text

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity by Skepper, Colin K, Moreau, Robert J, Appleton, Brent A, Benton, Bret M, Drumm, Joseph E, Feng, Brian Y, Geng, Mei, Hu, Cheng, Li, Cindy, Lingel, Andreas, Lu, Yipin, Mamo, Mulugeta, Mergo, Wosenu, Mostafavi, Mina, Rath, Christopher M, Steffek, Micah, Takeoka, Kenneth T, Uehara, Kyoko, Wang, Lisha, Wei, Jun-Rong, Xie, Lili, Xu, Wenjian, Zhang, Qiong, de Vicente, Javier

“…In the preceding manuscript [Moreau et al. 2018, 10.1021/acs.jmedchem.7b01691 ] we described a successful fragment-based lead discovery (FBLD) strategy for…”
Get full text

Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria by Moreau, Robert J, Skepper, Colin K, Appleton, Brent A, Blechschmidt, Anke, Balibar, Carl J, Benton, Bret M, Drumm, Joseph E, Feng, Brian Y, Geng, Mei, Li, Cindy, Lindvall, Mika K, Lingel, Andreas, Lu, Yipin, Mamo, Mulugeta, Mergo, Wosenu, Polyakov, Valery, Smith, Thomas M, Takeoka, Kenneth, Uehara, Kyoko, Wang, Lisha, Wei, Jun-Rong, Weiss, Andrew H, Xie, Lili, Xu, Wenjian, Zhang, Qiong, de Vicente, Javier

“…The discovery and development of new antibiotics capable of curing infections due to multidrug-resistant and pandrug-resistant Gram-negative bacteria are a…”
Get full text

Design and Discovery of N‑(2-Methyl-5′-morpholino-6′-((tetrahydro‑2H‑pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers by Nishiguchi, Gisele A, Rico, Alice, Tanner, Huw, Aversa, Robert J, Taft, Benjamin R, Subramanian, Sharadha, Setti, Lina, Burger, Matthew T, Wan, Lifeng, Tamez, Victoriano, Smith, Aaron, Lou, Yan, Barsanti, Paul A, Appleton, Brent A, Mamo, Mulugeta, Tandeske, Laura, Dix, Ina, Tellew, John E, Huang, Shenlin, Mathews Griner, Lesley A, Cooke, Vesselina G, Van Abbema, Anne, Merritt, Hanne, Ma, Sylvia, Gampa, Kalyani, Feng, Fei, Yuan, Jing, Wang, Yingyun, Haling, Jacob R, Vaziri, Sepideh, Hekmat-Nejad, Mohammad, Jansen, Johanna M, Polyakov, Valery, Zang, Richard, Sethuraman, Vijay, Amiri, Payman, Singh, Mallika, Lees, Emma, Shao, Wenlin, Stuart, Darrin D, Dillon, Michael P, Ramurthy, Savithri

“…RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need. The exquisite dependency on CRAF kinase in KRAS mutant…”
Get full text

Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis by Manjunatha, Ujjini H., Lakshminarayana, Suresh B., Jumani, Rajiv S., Chao, Alexander T., Young, Joseph M., Gable, Jonathan E., Knapp, Mark, Hanna, Imad, Galarneau, Jean-Rene, Cantwell, John, Kulkarni, Upendra, Turner, Michael, Lu, Peichao, Darrell, Kristen H., Watson, Lucy C., Chan, Katherine, Patra, Debjani, Mamo, Mulugeta, Luu, Catherine, Cuellar, Carlos, Shaul, Jacob, Xiao, Linda, Chen, Ying-Bo, Carney, Shannon K., Lakshman, Jay, Osborne, Colin S., Zambriski, Jennifer A., Aziz, Natasha, Sarko, Christopher, Diagana, Thierry T.

“…Diarrhoeal disease caused by Cryptosporidium is a major cause of morbidity and mortality in young and malnourished children from low- and middle-income…”
Get full text

Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate by Judge, Russell A., Vasudevan, Anil, Scott, Victoria E., Simler, Gricelda H., Pratt, Steve D., Namovic, Marian T., Putman, C. Brent, Aguirre, Ana, Stoll, Vincent S., Mamo, Mulugeta, Swann, Steven I., Cassar, Steven C., Faltynek, Connie R., Kage, Karen L., Boyce‐Rustay, Janel M., Hobson, Adrian D.

“…We describe the design, synthesis, and structure–activity relationships (SARs) of a series of 2‐aminobenzothiazole inhibitors of Rho kinases (ROCKs) 1 and 2,…”
Get full text

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo by Luo, Yan, Shoemaker, Alexander R, Liu, Xuesong, Woods, Keith W, Thomas, Sheela A, de Jong, Ron, Han, Edward K, Li, Tongmei, Stoll, Vincent S, Powlas, Jessica A, Oleksijew, Anatol, Mitten, Michael J, Shi, Yan, Guan, Ran, McGonigal, Thomas P, Klinghofer, Vered, Johnson, Eric F, Leverson, Joel D, Bouska, Jennifer J, Mamo, Mulugeta, Smith, Richard A, Gramling-Evans, Emily E, Zinker, Bradley A, Mika, Amanda K, Nguyen, Phong T, Oltersdorf, Tilman, Rosenberg, Saul H, Li, Qun, Giranda, Vincent L

“…The Akt kinases are central nodes in signal transduction pathways that are important for cellular transformation and tumor progression. We report the…”
Get full text

Corrigendum: Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate by Judge, Russell A., Vasudevan, Anil, Scott, Victoria E., Simler, Gricelda H., Pratt, Steve D., Namovic, Marian T., Putman, C. Brent, Aguirre, Ana, Stoll, Vincent S., Mamo, Mulugeta, Swann, Steven I., Cassar, Steven C., Faltynek, Connie R., Kage, Karen L., Boyce‐Rustay, Janel M., Hobson, Adrian D.

Get full text

Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt by Zhu, Gui-Dong, Gong, Jianchun, Gandhi, Viraj B., Woods, Keith, Luo, Yan, Liu, Xuesong, Guan, Ran, Klinghofer, Vered, Johnson, Eric F., Stoll, Vincent S., Mamo, Mulugeta, Li, Qun, Rosenberg, Saul H., Giranda, Vincent L.

“…We have designed and synthesized a series of potent pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt. The best compound in this series showed…”
Get full text

Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension by Zhu, Gui-Dong, Gandhi, Viraj B, Gong, Jianchun, Thomas, Sheela, Woods, Keith W, Song, Xiaohong, Li, Tongmei, Diebold, R. Bruce, Luo, Yan, Liu, Xuesong, Guan, Ran, Klinghofer, Vered, Johnson, Eric F, Bouska, Jennifer, Olson, Amanda, Marsh, Kennan C, Stoll, Vincent S, Mamo, Mulugeta, Polakowski, James, Campbell, Thomas J, Martin, Ruth L, Gintant, Gary A, Penning, Thomas D, Li, Qun, Rosenberg, Saul H, Giranda, Vincent L

“…Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising…”
Get full text

P1-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors with Potent Antiviral Activity against Drug-Resistant Viruses by DeGoey, David A, Grampovnik, David J, Chen, Hui-Ju, Flosi, William J, Klein, Larry L, Dekhtyar, Tatyana, Stoll, Vincent, Mamo, Mulugeta, Molla, Akhteruzzaman, Kempf, Dale J

“…Because there is currently no cure for HIV infection, patients must remain on long-term drug therapy, leading to concerns over potential drug side effects and…”
Get full text

2-Pyridyl P1′-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors (A-792611 and A-790742) with Potential for Convenient Dosing and Reduced Side Effects by DeGoey, David A, Grampovnik, David J, Flentge, Charles A, Flosi, William J, Chen, Hui-ju, Yeung, Clinton M, Randolph, John T, Klein, Larry L, Dekhtyar, Tatyana, Colletti, Lynn, Marsh, Kennan C, Stoll, Vincent, Mamo, Mulugeta, Morfitt, David C, Nguyen, Bach, Schmidt, James M, Swanson, Sue J, Mo, Hongmei, Kati, Warren M, Molla, Akhteruzzaman, Kempf, Dale J

“…A series of symmetry-based HIV protease inhibitors was designed and synthesized. Modification of the core regiochemistry and stereochemistry significantly…”
Get full text